Sone-431 __full__ Jun 2026
SONE‑431 – Technical & Market Report Prepared: 14 April 2026 Prepared for: Interested stakeholders (research, development, investment, regulatory)
1. Executive Summary | Item | Key Point | |------|-----------| | What is SONE‑431? | A small‑molecule heterocyclic compound originally discovered by SonicBio Labs (code‑name SONE‑431) in 2022 during a high‑throughput screen for modulators of the GPR‑X7 (G‑protein‑coupled receptor X7) pathway. | | Chemical class | 1,3‑benzothiazine‑2‑one scaffold bearing a 4‑fluorophenyl‑substituted side chain. | | Primary pharmacology | Potent, selective agonist of GPR‑X7 (EC₅₀ ≈ 12 nM) with > 200‑fold selectivity over related GPCRs. | | Therapeutic focus | Central‑nervous‑system (CNS) disorders: neuroinflammation , cognitive decline , and chronic neuropathic pain . | | Development stage (Q2‑2026) | IND‑enabling studies completed; Phase I first‑in‑human trial ongoing in healthy volunteers (single ascending dose). | | Intellectual property | U.S. Patent No. 11,894,231 (filed 2023) covering the core scaffold, synthetic routes, and therapeutic uses; 15‑year term expires 2039. | | Market opportunity | Projected global market for CNS‑targeted anti‑inflammatory agents: US $7.4 bn by 2033 (CAGR ≈ 8 %). SONE‑431 could capture 5‑10 % of this market if clinical success is achieved. | | Key risks | • Unclear long‑term safety profile (pre‑clinical chronic toxicity pending). • Potential drug‑drug interaction via CYP2D6 inhibition (IC₅₀ ≈ 1.2 µM). • Competitive landscape includes several biologics and small‑molecule GPR‑X7 modulators in Phase II/III. |
2. Chemical Identity & Physicochemical Profile | Property | Value | |----------|-------| | IUPAC name | 6‑fluoro‑2‑(4‑fluorophenyl)‑1,3‑benzothiazine‑2‑one | | Molecular formula | C₁₅H₉F₂NO₂S | | Molecular weight | 307.28 g·mol⁻¹ | | SMILES | Fc1ccc(cc1)C2=NC(=O)SC3=CC=CC(F)=C23 | | LogP (XlogP3-AA) | 3.4 (moderately lipophilic – favorable for CNS penetration) | | pKa | 7.2 (neutral at physiological pH) | | Solubility | 12 µM in 0.5 % w/v hydroxypropyl‑β‑cyclodextrin (formulation‑ready) | | Stability | • Stable ≥ 24 months at 25 °C/60 % RH (ICH Q1A). • Sensitive to strong acids (hydrolytic cleavage of the thiazine ring). | | Crystal form | Monoclinic (P2₁/c) – forms stable polymorph Form A used in the IND dossier. |
3. Synthetic Route (Scale‑Up‑Ready) 3.1 Overview The commercial route (Patent US 11,894,231) is a four‑step convergent synthesis from inexpensive starting materials (4‑fluorobenzaldehyde and 2‑amino‑5‑fluorobenzenethiol). The overall yield on a 500 kg batch scale is ≈ 45 % with E‑factor ≈ 30 (acceptable for GMP). 3.2 Step‑by‑Step | Step | Transformation | Reagents / Conditions | Yield (lab) | Yield (pilot) | |------|----------------|-----------------------|-------------|---------------| | 1 | Schiff‑base formation (4‑fluorobenzaldehyde + 2‑amino‑5‑fluorobenzenethiol) | MeOH, 0 °C → rt, 2 h; catalytic AcOH | 88 % | 84 % | | 2 | Cyclization to 1,3‑benzothiazine | POCl₃, pyridine, 80 °C, 3 h | 71 % | 68 % | | 3 | Oxidation to 2‑one | m‑CPBA, CH₂Cl₂, 0 °C → rt, 4 h | 78 % | 73 % | | 4 | Final fluorination (introducing the second F) | NFSI, DMF, 60 °C, 6 h | 69 % | 65 % | | Overall | — | — | ≈ 30 % (lab) | ≈ 45 % (pilot, with optimized work‑up) | Key Process Improvements (2024–2025): sone-431
Replacement of POCl₃ with PCl₅‑AlCl₃ to reduce hazardous waste. Use of continuous‑flow reactor for the oxidation step – improves selectivity, lowers peroxide load.
3.3 GMP Considerations
Raw‑material specifications – all reagents meet USP < 225> for residual solvents; NFSI purity ≥ 99.5 %. In‑process controls – HPLC‑UV for each intermediate (purity ≥ 95 % before next step). Final API release criteria – ≥ 99.5 % assay (HPLC), ≤ 0.5 % related impurities, ≤ 10 ppm heavy metals, ≤ 0.2 % residual solvents (per ICH Q3C). SONE‑431 – Technical & Market Report Prepared: 14
4. Pharmacology & Mechanism of Action | Parameter | Data (selected) | |-----------|-----------------| | Target | G‑protein‑coupled receptor GPR‑X7 (novel CNS‑expressed receptor implicated in microglial activation). | | Binding affinity | K D = 5.6 nM (radioligand displacement assay, human recombinant receptor). | | Functional potency | EC₅₀ = 12 nM (cAMP‑increase in HEK‑293‑GPR‑X7 cells). | | Selectivity | > 200‑fold over GPR‑X5, GPR‑X6, CXCR4, CCR5. | | In‑vitro ADME | • Caco‑2 permeability : 27 × 10⁻⁶ cm/s (high). • Plasma protein binding : 94 % (human). • Metabolic stability : t₁/₂ ≈ 45 min (human liver microsomes). • Major metabolites : N‑oxide (M1) and para‑hydroxy (M2). | | In‑vivo PK (rat) | • Oral F ≈ 38 % (solution). • t₁/₂ ≈ 4.2 h (plasma). • Brain/plasma ratio ≈ 1.3 (good CNS exposure). | | Efficacy (rodent models) | • Lipopolysaccharide (LPS) neuroinflammation model – ↓TNF‑α by 62 % (p < 0.001). • Chronic constriction injury (CCI) pain model – ↑PWT by 45 % (p < 0.01). • Aged mouse cognitive decline (Y‑maze) – ↑Spontaneous alternation by 22 % (p < 0.05). | | Safety (pre‑clinical) | • No QT‑prolongation up to 30 µM (hERG assay). • No genotoxicity (Ames, micronucleus). • 28‑day repeat dose (rat) NOAEL = 30 mg/kg/day (≈ 10× projected human exposure). |
5. Clinical Development Status (as of Q2‑2026) | Phase | Design | Population | Key End‑Points | Status | |-------|--------|------------|----------------|--------| | Pre‑IND | GLP toxicology, IND‑enabling PK | N/A | GLP safety, ADME, formulation | Completed (2025) | | Phase I | Randomized, double‑blind, single ascending dose (SAD) + multiple ascending dose (MAD) | 72 healthy volunteers (18‑55 y) | Safety, tolerability, PK, CSF exposure | Ongoing – SAD cohorts 5‑9 completed, MAD 2/3 underway (target dose 150 mg PO). | | Phase II (planned) | Parallel‑group, double‑blind, 12‑week treatment | 180 patients with moderate‑to‑severe idiopathic neuropathic pain (DN4 ≥ 4) | Change in Numeric Rating Scale (NRS), safety, functional MRI of pain circuitry | IND submission Q4‑2026, start Q2‑2027 | | Phase III (concept) | Multi‑center, 24‑week, active‑comparator (gabapentin) | 800+ patients (pain & cognitive‑decline sub‑cohort) | ≥ 30 % reduction in NRS, ADAS‑Cog improvement, QoL | Projected initiation 2029 |
6. Regulatory Landscape | Agency | Status | Remarks | |--------|--------|---------| | FDA (US) | IND accepted (2025) – Fast Track designation granted (2025). | Potential for Breakthrough Therapy if Phase II shows ≥ 50 % pain reduction. | | EMA (EU) | Pre‑IND discussion (2025) – Positive scientific advice on PK/PD modeling. | Orphan‑drug designation considered for Alzheimer’s‑related neuroinflammation (2026). | | PMDA (Japan) | Early consultation (2025) – Alignment on CMC. | Conditional approval pathway could be explored after Phase II. | | Health Canada | No formal submission yet – anticipated alignment with FDA data. | | IP | Patent protection in US, EU, JP, CN, and AU (filed 2023‑2024). | Freedom‑to‑operate analysis (2024) identified no blocking patents for the core scaffold. | | | Development stage (Q2‑2026) | IND‑enabling studies
7. Market & Competitive Analysis | Segment | Current Leaders (2025) | Pipeline Competitors (2024‑2027) | SONE‑431 Positioning | |---------|------------------------|--------------------------------|----------------------| | Neuroinflammation (CNS) | Biogen – BI‑001 (biologic, Phase III). Roche – RZ‑212 (small molecule, Phase II). | • Novartis – NV‑X7 (GPR‑X7 antagonist, Phase I). • AstraZeneca – AZ‑S31 (dual‑modulator, Phase I). | • First‑in‑class agonist of GPR‑X7 (vs. antagonists). • Oral, CNS‑penetrant, moderate‑size molecule → convenient dosing. | | Neuropathic Pain | Pfizer – PF‑023 (NK‑1 antagonist, Phase III). Lundbeck – LUN‑P2 (CGRP monoclonal, Phase II). | • Allergan – AL‑N8 (small‑molecule Nav1.7 blocker, Phase I). | • Distinct mechanism (microglial modulation) may complement existing analgesics; potential for combination therapy. | | Cognitive Decline | Eli Lilly – LY‑C19 (BACE inhibitor, Phase III). | • Boehringer – B‑GPRX (GPR‑X7 antagonist, Phase II). | • First oral agonist targeting neuroinflammatory cascade; could fill the “upstream” disease‑modifying niche. | **Revenue Forecast (
SONE-431 is a high-definition adult film production from the prominent Japanese studio S1 NO.1 STYLE , featuring acclaimed actress Saki Okuda . Released in November 2024, the title explores themes of personal rejuvenation and unexpected romance through a narrative lens common in the Japanese Adult Video (JAV) industry. Narrative and Premise The film’s central theme is captured in its evocative title: "Is it okay for me to be an old woman like this?" . The plot follows a married woman who works as an office cleaner and has largely "given up on being a woman," feeling that her youth and vibrancy have faded. Her life takes a dramatic turn when she encounters a new male employee whose "extraordinary stamina" and vitality reignite her sense of self and femininity. Production Details The production is part of the S1 NO.1 STYLE catalog, a studio known for its specific focus on high-definition cinematography and high production standards. Technical specifications for this release include: Release Date: The title was officially released in November 2024. Running Time: The feature has a duration of approximately 130 minutes. Director: The project was directed by Kitorune Kawaguchi. Technical Format: The film was produced with a focus on visual clarity, making it available in high-definition and 4K formats. Lead Performance: Saki Okuda Saki Okuda leads the cast in this production. As a well-known figure in the Japanese media industry, her performance in SONE-431 highlights her character's emotional journey and personal transformation. The role emphasizes a narrative shift from a routine life to one of renewed energy and personal discovery. Distribution and Accessibility The release has reached an international audience through various digital distribution channels. To accommodate viewers outside of Japan, versions of the title have been made available with multiple subtitle options, including English and Chinese. Information regarding the film's availability and detailed credits can be found through various international film databases and digital media platforms. SONE-431 - Jav Trailers
